A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)
Conditions
Liver Cancer
Trial Phase
Trial Purpose and Description
Trial Purpose
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
- Sponsor:
- National Cancer Institute (NCI)
- Dates:
- April 2011
- Last Updated:
- Study HIC#:
- 1102008042
Clinicaltrials.gov ID: Yale5024181
For more information about this trial, contact:
Investigator
Stacey Stein, MMS, MD
Principal Investigator
